<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35348849</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1432-2013</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>474</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Pflugers Archiv : European journal of physiology</Title>
          <ISOAbbreviation>Pflugers Arch</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Lipid metabolic reprogramming by hypoxia-inducible factor-1 in the hypoxic tumour microenvironment.</ArticleTitle>
        <Pagination>
          <StartPage>591</StartPage>
          <EndPage>601</EndPage>
          <MedlinePgn>591-601</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00424-022-02683-x</ELocationID>
        <Abstract>
          <AbstractText>Cancer cells rewire metabolic processes to adapt to the nutrient- and oxygen-deprived tumour microenvironment, thereby promoting their proliferation and metastasis. Previous research has shown that modifying glucose metabolism, the Warburg effect, makes glycolytic cancer cells more invasive and aggressive. Lipid metabolism has also been receiving attention because lipids function as energy sources and signalling molecules. Because obesity is a risk factor for various cancer types, targeting lipid metabolism may be a promising cancer therapy. Here, we review the lipid metabolic reprogramming in cancer cells mediated by hypoxia-inducible factor-1 (HIF-1). HIF-1 is the master transcription factor for tumour growth and metastasis by transactivating genes related to proliferation, survival, angiogenesis, invasion, and metabolism. The glucose metabolic shift (the Warburg effect) is mediated by HIF-1. Recent research on HIF-1-related lipid metabolic reprogramming in cancer has confirmed that HIF-1 also modifies lipid accumulation, β-oxidation, and lipolysis in cancer, triggering its progression. Therefore, targeting lipid metabolic alterations by HIF-1 has therapeutic potential for cancer. We summarize the role of the lipid metabolic shift mediated by HIF-1 in cancer and its putative applications for cancer therapy.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Seo</LastName>
            <ForeName>Jieun</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, 03080, South Korea.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, Seoul National University College of Medicine, Seoul, 03080, South Korea.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Faculty of Engineering, Yokohama National University, Yokohama, 240-8501, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Kanagawa Institute of Industrial Science and Technology, Kawasaki, 213-0012, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Yun</LastName>
            <ForeName>Jeong-Eun</ForeName>
            <Initials>JE</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, 03080, South Korea.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, Seoul National University College of Medicine, Seoul, 03080, South Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kim</LastName>
            <ForeName>Sung Joon</ForeName>
            <Initials>SJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, 03080, South Korea.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, Seoul National University College of Medicine, Seoul, 03080, South Korea.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Ischemic/Hypoxic Disease Institute, Seoul National University College of Medicine, Seoul, 03080, South Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chun</LastName>
            <ForeName>Yang-Sook</ForeName>
            <Initials>YS</Initials>
            <Identifier Source="ORCID">0000-0002-1261-9498</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, 03080, South Korea. chunys@snu.ac.kr.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, Seoul National University College of Medicine, Seoul, 03080, South Korea. chunys@snu.ac.kr.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Ischemic/Hypoxic Disease Institute, Seoul National University College of Medicine, Seoul, 03080, South Korea. chunys@snu.ac.kr.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>28</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>Pflugers Arch</MedlineTA>
        <NlmUniqueID>0154720</NlmUniqueID>
        <ISSNLinking>0031-6768</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051793">Hypoxia-Inducible Factor 1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051795">Hypoxia-Inducible Factor 1, alpha Subunit</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008055">Lipids</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D006019" MajorTopicYN="N">Glycolysis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000860" MajorTopicYN="N">Hypoxia</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051793" MajorTopicYN="N">Hypoxia-Inducible Factor 1</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051795" MajorTopicYN="N">Hypoxia-Inducible Factor 1, alpha Subunit</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008055" MajorTopicYN="N">Lipids</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="Y">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Cancer therapy</Keyword>
        <Keyword MajorTopicYN="N">Hypoxia-inducible factor-1</Keyword>
        <Keyword MajorTopicYN="N">Lipid metabolism</Keyword>
        <Keyword MajorTopicYN="N">Tumour microenvironment</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>29</Day>
          <Hour>12</Hour>
          <Minute>21</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35348849</ArticleId>
        <ArticleId IdType="doi">10.1007/s00424-022-02683-x</ArticleId>
        <ArticleId IdType="pii">10.1007/s00424-022-02683-x</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Kory N, Farese RV, Jr., Walther T C. (2016) Targeting fat: mechanisms of protein localization to lipid droplets. Trends Cell Biol 26:535–546. https://doi.org/10.1016/j.tcb.2016.02.007</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tcb.2016.02.007</ArticleId>
            <ArticleId IdType="pubmed">26995697</ArticleId>
            <ArticleId IdType="pmc">4976449</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murphy DJ (2012) The dynamic roles of intracellular lipid droplets: from archaea to mammals. Protoplasma 249:541–585. https://doi.org/10.1007/s00709-011-0329-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00709-011-0329-7</ArticleId>
            <ArticleId IdType="pubmed">22002710</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thiam AR, Farese RV, Jr., Walther T C. (2013) The biophysics and cell biology of lipid droplets. Nat Rev Mol Cell Biol 14:775–786. https://doi.org/10.1038/nrm3699</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrm3699</ArticleId>
            <ArticleId IdType="pubmed">24220094</ArticleId>
            <ArticleId IdType="pmc">4526153</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Walther TC, Farese RV, Jr. (2012) Lipid droplets and cellular lipid metabolism. Annu Rev Biochem 81:687–714. https://doi.org/10.1146/annurev-biochem-061009-102430</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev-biochem-061009-102430</ArticleId>
            <ArticleId IdType="pubmed">22524315</ArticleId>
            <ArticleId IdType="pmc">3767414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Olzmann JA, Carvalho P (2019) Dynamics and functions of lipid droplets. Nat Rev Mol Cell Biol 20:137–155. https://doi.org/10.1038/s41580-018-0085-z</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41580-018-0085-z</ArticleId>
            <ArticleId IdType="pubmed">30523332</ArticleId>
            <ArticleId IdType="pmc">6746329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>English D (1996) Phosphatidic acid: a lipid messenger involved in intracellular and extracellular signalling. Cell Signal 8:341–347. https://doi.org/10.1016/0898-6568(95)00076-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0898-6568(95)00076-3</ArticleId>
            <ArticleId IdType="pubmed">8911682</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andresen BT, Rizzo MA, Shome K, Romero G (2002) The role of phosphatidic acid in the regulation of the Ras/MEK/Erk signaling cascade. FEBS Lett 531:65–68. https://doi.org/10.1016/S0014-5793(02)03483-X</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0014-5793(02)03483-X</ArticleId>
            <ArticleId IdType="pubmed">12401205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jeong DW, Lee SB, Chun YS (2021) How cancer cells remodel lipid metabolism: strategies targeting transcription factors. Lipids Health Dis 20:163. https://doi.org/10.1186/s12944-021-01593-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12944-021-01593-8</ArticleId>
            <ArticleId IdType="pubmed">34775964</ArticleId>
            <ArticleId IdType="pmc">8590761</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Papackova Z, Cahova M (2015) Fatty acid signaling: the new function of intracellular lipases. Int J Mol Sci 16:3831–3855. https://doi.org/10.3390/ijms16023831</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms16023831</ArticleId>
            <ArticleId IdType="pubmed">25674855</ArticleId>
            <ArticleId IdType="pmc">4346929</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nadolski MJ, Linder ME (2007) Protein lipidation Febs Journal 274:5202–5210. https://doi.org/10.1111/j.1742-4658.2007.06056.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1742-4658.2007.06056.x</ArticleId>
            <ArticleId IdType="pubmed">17892486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lega IC, Lipscombe LL (2020) Review: diabetes, obesity, and cancer-pathophysiology and clinical implications. Endocr Rev 41:33–52. https://doi.org/10.1210/endrev/bnz014</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/endrev/bnz014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seo JE, Kim KS, Park JW, Cho JY, Chang H, Fukuda J, Hong KY, Chun YS (2021) Metastasis-on-a-chip reveals adipocyte-derived lipids trigger cancer cell migration via HIF-1α activation in cancer cells. Biomaterials 269:120622. https://doi.org/10.1016/j.biomaterials.2020.120622</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biomaterials.2020.120622</ArticleId>
            <ArticleId IdType="pubmed">33385686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beloribi-Djefaflia S, Vasseur S, Guillaumond F (2016) Lipid metabolic reprogramming in cancer cells. Oncogenesis 5:e189. https://doi.org/10.1038/oncsis.2015.49</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/oncsis.2015.49</ArticleId>
            <ArticleId IdType="pubmed">26807644</ArticleId>
            <ArticleId IdType="pmc">4728678</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ryan HE, Poloni M, McNulty W, Elson D, Gassmann M, Arbeit JM, Johnson RS (2000) Hypoxia-inducible factor-1α is a positive factor in solid tumor growth. Can Res 60:4010–4015</Citation>
        </Reference>
        <Reference>
          <Citation>Semenza GL, Wang GL (1992) A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 12:5447–5454. https://doi.org/10.1128/mcb.12.12.5447-5454.1992</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/mcb.12.12.5447-5454.1992</ArticleId>
            <ArticleId IdType="pubmed">1448077</ArticleId>
            <ArticleId IdType="pmc">360482</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang BH, Rue E, Wang GL, Roe R, Semenza GL (1996) Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J Biol Chem 271:17771–17778. https://doi.org/10.1074/jbc.271.30.17771</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.271.30.17771</ArticleId>
            <ArticleId IdType="pubmed">8663540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dengler VL, Galbraith M, Espinosa JM (2014) Transcriptional regulation by hypoxia inducible factors. Crit Rev Biochem Mol Biol 49:1–15. https://doi.org/10.3109/10409238.2013.838205</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/10409238.2013.838205</ArticleId>
            <ArticleId IdType="pubmed">24099156</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li H, Ko HP, Whitlock JP (1996) Induction of phosphoglycerate kinase 1 gene expression by hypoxia. Roles of Arnt and HIF1alpha. J Biol Chem 271:21262–21267. https://doi.org/10.1074/jbc.271.35.21262</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.271.35.21262</ArticleId>
            <ArticleId IdType="pubmed">8702901</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, von Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, Ratcliffe PJ (2001) Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292:468–472. https://doi.org/10.1126/science.1059796</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1059796</ArticleId>
            <ArticleId IdType="pubmed">11292861</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, Pavletich N, Chau V, Kaelin WG (2000) Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2:423–427. https://doi.org/10.1038/35017054</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/35017054</ArticleId>
            <ArticleId IdType="pubmed">10878807</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vaupel P, Mayer A (2007) Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 26:225–239. https://doi.org/10.1007/s10555-007-9055-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10555-007-9055-1</ArticleId>
            <ArticleId IdType="pubmed">17440684</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maxwell PH, Pugh CW, Ratcliffe PJ (2001) Activation of the HIF pathway in cancer. Curr Opin Genet Dev 11:293–299. https://doi.org/10.1016/s0959-437x(00)00193-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0959-437x(00)00193-3</ArticleId>
            <ArticleId IdType="pubmed">11377966</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Isaacs JS, Jung YJ, Mimnaugh EG, Martinez A, Cuttitta F, Neckers LM (2002) Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J Biol Chem 277:29936–29944. https://doi.org/10.1074/jbc.M204733200</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M204733200</ArticleId>
            <ArticleId IdType="pubmed">12052835</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu YV, Baek JH, Zhang H, Diez R, Cole RN, Semenza GL (2007) RACK1 competes with HSP90 for binding to HIF-1alpha and is required for O(2)-independent and HSP90 inhibitor-induced degradation of HIF-1alpha. Mol Cell 25:207–217. https://doi.org/10.1016/j.molcel.2007.01.001</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2007.01.001</ArticleId>
            <ArticleId IdType="pubmed">17244529</ArticleId>
            <ArticleId IdType="pmc">2563152</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Richard DE, Berra E, Pouyssegur J (2000) Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1alpha in vascular smooth muscle cells. J Biol Chem 275:26765–26771. https://doi.org/10.1074/jbc.M003325200</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M003325200</ArticleId>
            <ArticleId IdType="pubmed">10837481</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zelzer E, Levy Y, Kahana C, Shilo BZ, Rubinstein M, Cohen B (1998) Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1alpha/ARNT. EMBO J 17:5085–5094. https://doi.org/10.1093/emboj/17.17.5085</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/emboj/17.17.5085</ArticleId>
            <ArticleId IdType="pubmed">9724644</ArticleId>
            <ArticleId IdType="pmc">1170836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, Simons JW, Semenza GL (2000) Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60:1541–1545</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10749120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haase VH (2013) Regulation of erythropoiesis by hypoxia-inducible factors. Blood Rev 27:41–53. https://doi.org/10.1016/j.blre.2012.12.003</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.blre.2012.12.003</ArticleId>
            <ArticleId IdType="pubmed">23291219</ArticleId>
            <ArticleId IdType="pmc">3731139</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu X, Kang Y (2010) Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin Cancer Res 16:5928–5935. https://doi.org/10.1158/1078-0432.CCR-10-1360</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-10-1360</ArticleId>
            <ArticleId IdType="pubmed">20962028</ArticleId>
            <ArticleId IdType="pmc">3005023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Welker MW, Trojan J (2013) Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety. Cancer Manag Res 5:337–347. https://doi.org/10.2147/CMAR.S35029</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/CMAR.S35029</ArticleId>
            <ArticleId IdType="pubmed">24204170</ArticleId>
            <ArticleId IdType="pmc">3804539</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang MH, Wu MZ, Chiou SH, Chen PM, Chang SY, Liu CJ, Teng SC, Wu KJ (2008) Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat Cell Biol 10:295–305. https://doi.org/10.1038/ncb1691</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb1691</ArticleId>
            <ArticleId IdType="pubmed">18297062</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Denko NC (2008) Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 8:705–713. https://doi.org/10.1038/nrc2468</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc2468</ArticleId>
            <ArticleId IdType="pubmed">19143055</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harris AL (2002) Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2:38–47. https://doi.org/10.1038/nrc704</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc704</ArticleId>
            <ArticleId IdType="pubmed">11902584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kress S, Stein A, Maurer P, Weber B, Reichert J, Buchmann A, Huppert P, Schwarz M (1998) Expression of hypoxia-inducible genes in tumor cells. J Cancer Res Clin Oncol 124:315–320. https://doi.org/10.1007/s004320050175</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s004320050175</ArticleId>
            <ArticleId IdType="pubmed">9692838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodriguez H, Drouin R, Holmquist GP, Akman SA (1997) A hot spot for hydrogen peroxide-induced damage in the human hypoxia-inducible factor 1 binding site of the PGK 1 gene. Arch Biochem Biophys 338:207–212. https://doi.org/10.1006/abbi.1996.9820</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1006/abbi.1996.9820</ArticleId>
            <ArticleId IdType="pubmed">9028873</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3:721–732. https://doi.org/10.1038/nrc1187</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc1187</ArticleId>
            <ArticleId IdType="pubmed">13130303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Semenza GL (2010) HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev 20:51–56. https://doi.org/10.1016/j.gde.2009.10.009</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.gde.2009.10.009</ArticleId>
            <ArticleId IdType="pubmed">19942427</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dang CV, Semenza GL (1999) Oncogenic alterations of metabolism. Trends Biochem Sci 24:68–72. https://doi.org/10.1016/s0968-0004(98)01344-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0968-0004(98)01344-9</ArticleId>
            <ArticleId IdType="pubmed">10098401</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, Zhuang HM, Cinalli RM, Alavi A, Rudin CM, Thompson CB (2004) Akt stimulates aerobic glycolysis in cancer cells. Can Res 64:3892–3899. https://doi.org/10.1158/0008-5472.CAN-03-2904</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-03-2904</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liberti MV, Locasale JW (2016) The Warburg effect: how does it benefit cancer cells? Trends Biochem Sci 41:211–218. https://doi.org/10.1016/j.tibs.2015.12.001</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tibs.2015.12.001</ArticleId>
            <ArticleId IdType="pubmed">26778478</ArticleId>
            <ArticleId IdType="pmc">4783224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim J-w, Tchernyshyov I, Semenza GL, Dang CV (2006) HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 3:177–185. https://doi.org/10.1016/j.cmet.2006.02.002</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cmet.2006.02.002</ArticleId>
            <ArticleId IdType="pubmed">16517405</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holleran AL, Briscoe DA, Fiskum G, Kelleher JK (1995) Glutamine metabolism in AS-30D hepatoma cells. Evidence for its conversion into lipids via reductive carboxylation. Mol Cell Biochem 152:95–101. https://doi.org/10.1007/BF01076071</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF01076071</ArticleId>
            <ArticleId IdType="pubmed">8751155</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Daye D, Wellen KE (2012) Metabolic reprogramming in cancer: unraveling the role of glutamine in tumorigenesis. Semin Cell Dev Biol 23:362–369. https://doi.org/10.1016/j.semcdb.2012.02.002</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.semcdb.2012.02.002</ArticleId>
            <ArticleId IdType="pubmed">22349059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Metallo CM, Gameiro PA, Bell EL, Mattaini KR, Yang JJ, Hiller K, Jewell CM, Johnson ZR, Irvine DJ, Guarente L, Kelleher JK, Vander Heiden MG, Iliopoulos O, Stephanopoulos G (2012) Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 481:380–384. https://doi.org/10.1038/nature10602</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature10602</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wise DR, P.S. Ward P S, Shay J E, Cross J R, Gruber J J, Sachdeva U M, Platt J M, DeMatteo R G, Simon M C, Thompson C B. (2011) Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability. PNAS 108:19611–19616. https://doi.org/10.1073/pnas.1117773108</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1117773108</ArticleId>
            <ArticleId IdType="pubmed">22106302</ArticleId>
            <ArticleId IdType="pmc">3241793</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gameiro PA, Yang JJ, Metelo AM, Perez-Carro R, Baker R, Wang ZW, Arreola A, Rathmell WK, Olumi A, Lopez-Larrubia P, Stephanopoulos G, Iliopoulos O (2013) In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation. Cell Metab 17:372–385. https://doi.org/10.1016/j.cmet.2013.02.002</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cmet.2013.02.002</ArticleId>
            <ArticleId IdType="pubmed">23473032</ArticleId>
            <ArticleId IdType="pmc">4003458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun RC, Denko NC (2014) Hypoxic regulation of glutamine metabolism through HIF1 and SIAH2 supports lipid synthesis that is necessary for tumor growth. Cell Metab 19:285–292. https://doi.org/10.1016/j.cmet.2013.11.022</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cmet.2013.11.022</ArticleId>
            <ArticleId IdType="pubmed">24506869</ArticleId>
            <ArticleId IdType="pmc">3920584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoo HC, Yu YC, Sung Y, Han JM (2020) Glutamine reliance in cell metabolism. Exp Mol Med 52:1496–1516. https://doi.org/10.1038/s12276-020-00504-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s12276-020-00504-8</ArticleId>
            <ArticleId IdType="pubmed">32943735</ArticleId>
            <ArticleId IdType="pmc">8080614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qiu JF, Zhang KL, Zhang XJ, Hu YJ, Li P, Shang CZ, Wan JB (2015) Abnormalities in plasma phospholipid fatty acid profiles of patients with hepatocellular carcinoma. Lipids 50:977–985. https://doi.org/10.1007/s11745-015-4060-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11745-015-4060-6</ArticleId>
            <ArticleId IdType="pubmed">26294003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mika A, Kobiela J, Czumaj A, Chmielewski M, Stepnowski P, Sledzinski T (2017) Hyper-elongation in colorectal cancer tissue - cerotic acid is a potential novel serum metabolic marker of colorectal malignancies. Cell Physiol Biochem 41:722–730. https://doi.org/10.1159/000458431</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000458431</ArticleId>
            <ArticleId IdType="pubmed">28214830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li F, Qin XZ, Chen HQ, Qiu L, Guo YM, Liu H, Chen GQ, Song GG, Wang XD, Li FJ, Guo S, Wang BH, Li ZL (2013) Lipid profiling for early diagnosis and progression of colorectal cancer using direct-infusion electrospray ionization Fourier transform ion cyclotron resonance mass spectrometry. Rapid Commun Mass Sp 27:24–34. https://doi.org/10.1002/rcm.6420</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/rcm.6420</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qiu YP, Cai GX, Zhou BS, Li D, Zhao AH, Xie GX, Li HK, Cai SJ, Xie D, Huang CZ, Ge WT, Zhou ZX, Xu LX, Jia WP, Zheng S, Yen Y, Jia W (2014) A distinct metabolic signature of human colorectal cancer with prognostic potential. Clin Cancer Res 20:2136–2146. https://doi.org/10.1158/1078-0432.CCR-13-1939</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-13-1939</ArticleId>
            <ArticleId IdType="pubmed">24526730</ArticleId>
            <ArticleId IdType="pmc">5902798</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pakiet A, Kobiela J, Stepnowski P, Sledzinski T, Mika A (2019) Changes in lipids composition and metabolism in colorectal cancer: a review. Lipids Health Dis 18:29. https://doi.org/10.1186/s12944-019-0977-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12944-019-0977-8</ArticleId>
            <ArticleId IdType="pubmed">30684960</ArticleId>
            <ArticleId IdType="pmc">6347819</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang JJ, Zhang LJ, Ye XX, Chen LY, Zhang LT, Gao YH, Kang JX, Cai C (2013) Characteristics of fatty acid distribution is associated with colorectal cancer prognosis. Prostag Leukotr Ess 88:355–360. https://doi.org/10.1016/j.plefa.2013.02.005</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.plefa.2013.02.005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baenke F, Peck B, Miess H, Schulze A (2013) Hooked on fat: the role of lipid synthesis in cancer metabolism and tumour development. Dis Model Mech 6:1353–1363. https://doi.org/10.1242/dmm.011338</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1242/dmm.011338</ArticleId>
            <ArticleId IdType="pubmed">24203995</ArticleId>
            <ArticleId IdType="pmc">3820259</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Solinas G, Boren J, Dulloo AG (2015) De novo lipogenesis in metabolic homeostasis: more friend than foe? Mol Metab 4:367–377. https://doi.org/10.1016/j.molmet.2015.03.004</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molmet.2015.03.004</ArticleId>
            <ArticleId IdType="pubmed">25973385</ArticleId>
            <ArticleId IdType="pmc">4421107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kusakabe T, Maeda M, Hoshi N, Sugino T, Watanabe K, Fukuda T, Suzuki T (2000) Fatty acid synthase is expressed mainly in adult hormone-sensitive cells or cells with high lipid metabolism and in proliferating fetal cells. J Histochem Cytochem 48:613–622. https://doi.org/10.1177/002215540004800505</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/002215540004800505</ArticleId>
            <ArticleId IdType="pubmed">10769045</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wagle S, Bui A, Ballard PL, Shuman H, Gonzales J, Gonzales LW (1999) Hormonal regulation and cellular localization of fatty acid synthase in human fetal lung. Am J Physiol-Lung C 277:L381–L390. https://doi.org/10.1152/ajplung.1999.277.2.L381</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/ajplung.1999.277.2.L381</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hatzivassiliou G, Zhao FP, Bauer DE, Andreadis C, Shaw AN, Dhanak D, Hingorani SR, Tuveson DA, Thompson CB (2005) ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 8:311–321. https://doi.org/10.1016/j.ccr.2005.09.008</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2005.09.008</ArticleId>
            <ArticleId IdType="pubmed">16226706</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Migita T, Narita T, Nomura K, Miyagi E, Inazuka F, Matsuura M, Ushijima M, Mashima T, Seimiya H, Satoh Y, Okumura S, Nakagawa K, Ishikawa Y (2008) ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer. Can Res 68:8547–8554. https://doi.org/10.1158/0008-5472.CAN-08-1235</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-08-1235</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Wang YX, Shen L, Pang YX, Qiao Z, Liu PS (2012) Prognostic and therapeutic implications of increased ATP citrate lyase expression in human epithelial ovarian cancer. Oncol Rep 27:1156–1162. https://doi.org/10.3892/or.2012.1638</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/or.2012.1638</ArticleId>
            <ArticleId IdType="pubmed">22266777</ArticleId>
            <ArticleId IdType="pmc">3583602</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Svensson RU, Parker SJ, Eichner LJ, Kolar MJ, Wallace M, Brun SN, Lombardo PS, Van Nostrand JL, Hutchins A, Vera L, Gerken L, Greenwood J, Bhat S, Harriman G, Westlin WF, Harwood HJ, Saghatelian A, Kapeller R, Metallo CM, Shaw RJ (2016) Inhibition of acetyl-CoA carboxylase suppresses fatty acid synthesis and tumor growth of non-small-cell lung cancer in preclinical models. Nat Med 22:1108–1119. https://doi.org/10.1038/nm.4181</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm.4181</ArticleId>
            <ArticleId IdType="pubmed">27643638</ArticleId>
            <ArticleId IdType="pmc">5053891</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ogino S, Nosho K, Meyerhardt JA, Kirkner GJ, Chan AT, Kawasaki T, Giovannucci EL, Loda M, Fuchs CS (2008) Cohort study of fatty acid synthase expression and patient survival in colon cancer. J Clin Oncol 26:5713–5720. https://doi.org/10.1200/JCO.2008.18.2675</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2008.18.2675</ArticleId>
            <ArticleId IdType="pubmed">18955444</ArticleId>
            <ArticleId IdType="pmc">2630484</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shurbaji MS, Kalbfleisch JH, Thurmond TS (1996) Immunohistochemical detection of a fatty acid synthase (OA-519) as a predictor of progression of prostate cancer. Hum Pathol 27:917–921. https://doi.org/10.1016/s0046-8177(96)90218-x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0046-8177(96)90218-x</ArticleId>
            <ArticleId IdType="pubmed">8816886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takahiro T, Shinichi K, Toshimitsu S (2003) Expression of fatty acid synthase as a prognostic indicator in soft tissue sarcomas. Clin Cancer Res 9:2204–2212</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12796387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Visca P, Sebastiani V, Botti C, Diodoro MG, Lasagni RP, Romagnoli F, Brenna A, De Joannon BC, Donnorso RP, Lombardi G, Alo PL (2004) Fatty acid synthase (FAS) is a marker of increased risk of recurrence in lung carcinoma. Anticancer Res 24:4169–4173</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15736468</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Furuta E, Pai SK, Zhan R, Bandyopadhyay S, Watabe M, Mo YY, Hirota S, Hosobe S, Tsukada T, Miura K, Kamada S, Saito K, Iiizumi M, Liu W, Ericsson J, Watabe K (2008) Fatty acid synthase gene is up-regulated by hypoxia via activation of Akt and sterol regulatory element binding protein-1. Cancer Res 68:1003–1011. https://doi.org/10.1158/0008-5472.CAN-07-2489</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-07-2489</ArticleId>
            <ArticleId IdType="pubmed">18281474</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lewis CA, Brault C, Peck B, Bensaad K, Griffiths B, Mitter R, Chakravarty P, East P, Dankworth B, Alibhai D, Harris AL, Schulze A (2015) SREBP maintains lipid biosynthesis and viability of cancer cells under lipid- and oxygen-deprived conditions and defines a gene signature associated with poor survival in glioblastoma multiforme. Oncogene 34:5128–5140. https://doi.org/10.1038/onc.2014.439</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2014.439</ArticleId>
            <ArticleId IdType="pubmed">25619842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peciuliene I, Vilys L, Jakubauskiene E, Zaliauskiene L, Kanopka A (2019) Hypoxia alters splicing of the cancer associated Fas gene. Exp Cell Res 380:29–35. https://doi.org/10.1016/j.yexcr.2019.04.015</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.yexcr.2019.04.015</ArticleId>
            <ArticleId IdType="pubmed">31002816</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jung SY, Jeon HK, Choi JS, Kim YJ (2012) Reduced expression of FASN through SREBP-1 down-regulation is responsible for hypoxic cell death in HepG2 cells. J Cell Biochem 113:3730–3739. https://doi.org/10.1002/jcb.24247</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcb.24247</ArticleId>
            <ArticleId IdType="pubmed">22786746</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Balaban S, Shearer RF, Lee LS, van Geldermalsen M, Schreuder M, Shtein HC, Cairns R, Thomas KC, Fazakerley DJ, Grewal T, Holst J, Saunders DN, Hoy AJ (2017) Adipocyte lipolysis links obesity to breast cancer growth: adipocyte-derived fatty acids drive breast cancer cell proliferation and migration. Cancer Metab 5:1. https://doi.org/10.1186/s40170-016-0163-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40170-016-0163-7</ArticleId>
            <ArticleId IdType="pubmed">28101337</ArticleId>
            <ArticleId IdType="pmc">5237166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, Romero IL, Carey MS, Mills GB, Hotamisligil GS, Yamada SD, Peter ME, Gwin K, Lengyel E (2011) Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med 17:1498–1503. https://doi.org/10.1038/nm.2492</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm.2492</ArticleId>
            <ArticleId IdType="pubmed">22037646</ArticleId>
            <ArticleId IdType="pmc">4157349</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Su X, Abumrad NA (2009) Cellular fatty acid uptake: a pathway under construction. Trends Endocrin Met 20:72–77. https://doi.org/10.1016/j.tem.2008.11.001</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tem.2008.11.001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Calvo D, Gomez-Coronado D, Suarez Y, Lasuncion MA, Vega MA (1998) Human CD36 is a high affinity receptor for the native lipoproteins HDL, LDL, and VLDL. J Lipid Res 39:777–788. https://doi.org/10.1016/S0022-2275(20)32566-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0022-2275(20)32566-9</ArticleId>
            <ArticleId IdType="pubmed">9555943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Enciu AM, Radu E, Popescu ID, Hinescu ME, Ceafalan LC (2018) Targeting CD36 as biomarker for metastasis prognostic: how far from translation into clinical practice? Biomed Res Int 2018:7801202. https://doi.org/10.1155/2018/7801202</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2018/7801202</ArticleId>
            <ArticleId IdType="pubmed">30069479</ArticleId>
            <ArticleId IdType="pmc">6057354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McKillop LH, Girardi CA, Thompson KJ (2019) Role of fatty acid binding proteins (FABPs) in cancer development and progression. Cell Signal 62:109336. https://doi.org/10.1016/j.cellsig.2019.06.001</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cellsig.2019.06.001</ArticleId>
            <ArticleId IdType="pubmed">31170472</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bensaad K, Favaro E, Lewis CA, Peck B, Lord S, Collins JM, Pinnick KE, Wigfield S, Buffa FM, Li JL, Zhang Q, Wakelam MJO, Karpe F, Schulze A, Harris AL (2014) Fatty acid uptake and lipid storage induced by HIF-1alpha contribute to cell growth and survival after hypoxia-reoxygenation. Cell Rep 9:349–365. https://doi.org/10.1016/j.celrep.2014.08.056</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2014.08.056</ArticleId>
            <ArticleId IdType="pubmed">25263561</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gharpure KM, Pradeep S, Sans M, Rupaimoole R, Ivan C, Wu SY, Bayraktar E, Nagaraja AS, Mangala LS, Zhang XN, Haemmerle M, Hu W, Rodriguez-Aguayo C, McGuire M, Mak CSL, Chen XH, Tran MA, Villar-Prados A, Pena GA, Kondetimmanahalli R, Nini R, Koppula P, Ram P, Liu JS, Lopez-Berestein G, Baggerly K, Eberlin LS, Sood AK (2018) FABP4 as a key determinant of metastatic potential of ovarian cancer. Nat Commun 9:2923. https://doi.org/10.1038/s41467-018-04987-y</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-018-04987-y</ArticleId>
            <ArticleId IdType="pubmed">30050129</ArticleId>
            <ArticleId IdType="pmc">6062524</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seo J, Jeong D-W, Park J-W, Lee K-W, Fukuda J, Chun Y-S (2020) Fatty-acid-induced FABP5/HIF-1 reprograms lipid metabolism and enhances the proliferation of liver cancer cells. Communications Biology 3:638. https://doi.org/10.1038/s42003-020-01367-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s42003-020-01367-5</ArticleId>
            <ArticleId IdType="pubmed">33128030</ArticleId>
            <ArticleId IdType="pmc">7599230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seo JE, Yun JE, Fukuda J, Chun YS (2021) Tumor-intrinsic FABP5 is a novel driver for colon cancer cell growth via the HIF-1 signaling pathway. Cancer Genet 258:151–156. https://doi.org/10.1016/j.cancergen.2021.11.001</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cancergen.2021.11.001</ArticleId>
            <ArticleId IdType="pubmed">34775260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khor VK, Shen WJ, Kraemer FB (2013) Lipid droplet metabolism. Curr Opin Clin Nutr 16:632–637. https://doi.org/10.1097/MCO.0b013e3283651106</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MCO.0b013e3283651106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cabodevilla AG, Sanchez-Caballero L, Nintou E, Boiadjieva VG, Picatoste F, Gubern A, Claro E (2013) Cell survival during complete nutrient deprivation depends on lipid droplet-fueled beta-oxidation of fatty acids. J Biol Chem 288:27777–27788. https://doi.org/10.1074/jbc.M113.466656</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M113.466656</ArticleId>
            <ArticleId IdType="pubmed">23940052</ArticleId>
            <ArticleId IdType="pmc">3784694</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cotte AK, Aires V, Fredon M, Limagne E, Derangere V, Thibaudin M, Humblin E, Scagliarini A, de Barros JP, Hillon P, Ghiringhelli F, Delmas D (2018) Lysophosphatidylcholine acyltransferase 2-mediated lipid droplet production supports colorectal cancer chemoresistance. Nat Commun 9:322. https://doi.org/10.1038/s41467-017-02732-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-017-02732-5</ArticleId>
            <ArticleId IdType="pubmed">29358673</ArticleId>
            <ArticleId IdType="pmc">5778070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jarc E, Kump A, Malavasic P, Eichmann TO, Zimmermann R, Petan T (2018) Lipid droplets induced by secreted phospholipase A2 and unsaturated fatty acids protect breast cancer cells from nutrient and lipotoxic stress. Biochim Biophys Acta Mol Cell Biol Lipids 1863:247–265. https://doi.org/10.1016/j.bbalip.2017.12.006</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbalip.2017.12.006</ArticleId>
            <ArticleId IdType="pubmed">29229414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pucer A, Brglez V, Payre C, Pungercar J, Lambeau G, Petan T (2013) Group X secreted phospholipase A(2) induces lipid droplet formation and prolongs breast cancer cell survival. Mol Cancer 12:111. https://doi.org/10.1186/1476-4598-12-111</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1476-4598-12-111</ArticleId>
            <ArticleId IdType="pubmed">24070020</ArticleId>
            <ArticleId IdType="pmc">3852912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Accioly MT, Pacheco P, Maya-Monteiro CM, Carrossini N, Robbs BK, Oliveira SS, Kaufmann C, Morgado-Diaz JA, Bozza PT, Viola JP (2008) Lipid bodies are reservoirs of cyclooxygenase-2 and sites of prostaglandin-E2 synthesis in colon cancer cells. Cancer Res 68:1732–1740. https://doi.org/10.1158/0008-5472.CAN-07-1999</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-07-1999</ArticleId>
            <ArticleId IdType="pubmed">18339853</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geng F, Cheng X, Wu X, Yoo JY, Cheng C, Guo JY (2017) Correction: inhibition of SOAT1 suppresses glioblastoma growth via blocking SREBP-1-mediated lipogenesis. Clin Cancer Res 23:2127. https://doi.org/10.1158/1078-0432.CCR-17-0063</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-17-0063</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sebastiano MR, Konstantinidou G (2019) Targeting long chain Acyl-CoA synthetases for cancer therapy. Int J Mol Sci 20:3624. https://doi.org/10.3390/ijms20153624</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms20153624</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soupene E, Kuypers FA (2008) Mammalian long-chain Acyl-CoA synthetases. Exp Biol Med 233:507–521. https://doi.org/10.3181/0710-MR-287</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3181/0710-MR-287</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saponaro C, Gaggini M, Carli F, Gastaldelli A (2015) The subtle balance between lipolysis and lipogenesis: a critical point in metabolic homeostasis. Nutrients 7:9453–9474. https://doi.org/10.3390/nu7115475</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/nu7115475</ArticleId>
            <ArticleId IdType="pubmed">26580649</ArticleId>
            <ArticleId IdType="pmc">4663603</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mylonis I, Sembongi H, Befani C, Liakos P, Siniossoglou S, Simos G (2012) Hypoxia causes triglyceride accumulation by HIF-1-mediated stimulation of lipin 1 expression. J Cell Sci 125:3485–3493. https://doi.org/10.1242/jcs.106682</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1242/jcs.106682</ArticleId>
            <ArticleId IdType="pubmed">22467849</ArticleId>
            <ArticleId IdType="pmc">3516382</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Triantafyllou EA, Georgatsou E, Mylonis I, Simos G, Paraskeva E (2018) Expression of AGPAT2, an enzyme involved in the glycerophospholipid/triacylglycerol biosynthesis pathway, is directly regulated by HIF-1 and promotes survival and etoposide resistance of cancer cells under hypoxia. Biochim Biophys Acta Mol Cell Biol Lipids 1863:1142–1152. https://doi.org/10.1016/j.bbalip.2018.06.015</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbalip.2018.06.015</ArticleId>
            <ArticleId IdType="pubmed">29908837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qiu B, Ackerman D, Sanchez DJ, Li B, Ochocki JD, Grazioli A, Bobrovnikova-Marjon E, Diehl JA, Keith B, Simon MC (2015) HIF2 alpha-dependent lipid storage promotes endoplasmic reticulum homeostasis in clear-cell renal cell carcinoma. Cancer Discov 5:652–667. https://doi.org/10.1158/2159-8290.CD-14-1507</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-14-1507</ArticleId>
            <ArticleId IdType="pubmed">25829424</ArticleId>
            <ArticleId IdType="pmc">4456212</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duncan RE, Ahmadian M, Jaworski K, Sarkadi-Nagy E, Sul HS (2007) Regulation of lipolysis in adipocytes. Annu Rev Nutr 27:79–101. https://doi.org/10.1146/annurev.nutr.27.061406.093734</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev.nutr.27.061406.093734</ArticleId>
            <ArticleId IdType="pubmed">17313320</ArticleId>
            <ArticleId IdType="pmc">2885771</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carracedo A, Cantley LC, Pandolfi PP (2013) Cancer metabolism: fatty acid oxidation in the limelight. Nat Rev Cancer 13:227–232. https://doi.org/10.1038/nrc3483</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc3483</ArticleId>
            <ArticleId IdType="pubmed">23446547</ArticleId>
            <ArticleId IdType="pmc">3766957</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Houten SM, Violante S, Ventura FV, Wanders RJA (2016) The biochemistry and physiology of mitochondrial fatty acid beta-oxidation and its genetic disorders. Annu Rev Physiol 78:23–44. https://doi.org/10.1146/annurev-physiol-021115-105045</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev-physiol-021115-105045</ArticleId>
            <ArticleId IdType="pubmed">26474213</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang XD, Saarinen AM, Hitosugi T, Wang ZH, Wang LG, Ho TH, Liu J (2017) Inhibition of intracellular lipolysis promotes human cancer cell adaptation to hypoxia. Elife 6:e31132. https://doi.org/10.7554/eLife.31132</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7554/eLife.31132</ArticleId>
            <ArticleId IdType="pubmed">29256392</ArticleId>
            <ArticleId IdType="pmc">5739538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y, Ma Z, Zhao C, Wang Y, Wu G, Xiao J, McClain CJ, Li X, Feng W (2014) HIF-1alpha and HIF-2alpha are critically involved in hypoxia-induced lipid accumulation in hepatocytes through reducing PGC-1alpha-mediated fatty acid beta-oxidation. Toxicol Lett 226:117–123. https://doi.org/10.1016/j.toxlet.2014.01.033</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.toxlet.2014.01.033</ArticleId>
            <ArticleId IdType="pubmed">24503013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Du W, Zhang L, Brett-Morris A, Aguila B, Kerner J, Hoppel CL, Puchowicz M, Serra D, Herrero L, Rini BI, Campbell S, Welford SM (2017) HIF drives lipid deposition and cancer in ccRCC via repression of fatty acid metabolism. Nat Commun 8:1769. https://doi.org/10.1038/s41467-017-01965-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-017-01965-8</ArticleId>
            <ArticleId IdType="pubmed">29176561</ArticleId>
            <ArticleId IdType="pmc">5701259</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang D, Li T, Li X, Zhang L, Sun L, He X, Zhong X, Jia D, Song L, Semenza GL, Gao P, Zhang H (2014) HIF-1-mediated suppression of acyl-CoA dehydrogenases and fatty acid oxidation is critical for cancer progression. Cell Rep 8:1930–1942. https://doi.org/10.1016/j.celrep.2014.08.028</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2014.08.028</ArticleId>
            <ArticleId IdType="pubmed">25242319</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Porstmann T, Santos CR, Griffiths B, Cully M, Wu M, Leevers S, Griffiths JR, Chung YL, Schulze A (2008) SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab 8:224–236. https://doi.org/10.1016/j.cmet.2008.07.007</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cmet.2008.07.007</ArticleId>
            <ArticleId IdType="pubmed">18762023</ArticleId>
            <ArticleId IdType="pmc">2593919</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luyimbazi D, Akcakanat A, McAuliffe PF, Zhang L, Singh G, Gonzalez-Angulo AM, Chen HQ, Do KA, Zheng YH, Hung MC, Mills GB, Meric-Bernstam F (2010) Rapamycin regulates stearoyl CoA desaturase 1 expression in breast cancer. Mol Cancer Ther 9:2770–2784. https://doi.org/10.1158/1535-7163.MCT-09-0980</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-09-0980</ArticleId>
            <ArticleId IdType="pubmed">20876744</ArticleId>
            <ArticleId IdType="pmc">2965451</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Magaway C, Kim E, Jacinto E (2019) Targeting mTOR and metabolism in cancer: lessons and innovations. Cells 8:1584. https://doi.org/10.3390/cells8121584</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cells8121584</ArticleId>
            <ArticleId IdType="pmc">6952948</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Souza C, Chatterji BP (2015) HDAC inhibitors as novel anti-cancer therapeutics. Recent Pat Anticancer Drug Discov 10:145–162. https://doi.org/10.2174/1574892810666150317144511</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/1574892810666150317144511</ArticleId>
            <ArticleId IdType="pubmed">25782916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nunn A, Scopigno T, Pediconi N, Levrero M, Hagman H, Kiskis J, Enejder A (2016) The histone deacetylase inhibiting drug entinostat induces lipid accumulation in differentiated HepaRG cells. Sci Rep 6:28025. https://doi.org/10.1038/srep28025</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/srep28025</ArticleId>
            <ArticleId IdType="pubmed">27320682</ArticleId>
            <ArticleId IdType="pmc">4913258</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brockmueller A, Sameri S, Liskova A, Zhai KV, Varghese E, Samuel SM, Busselberg D, Kubatka P, Shakibaei M (2021) Resveratrol’s anti-cancer effects through the modulation of tumor glucose metabolism. Cancers 13:188. https://doi.org/10.3390/cancers13020188</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers13020188</ArticleId>
            <ArticleId IdType="pmc">7825813</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen D, Frezza M, Schmitt S, Kanwar J, Dou QP (2011) Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Tar 11:239–253. https://doi.org/10.2174/156800911794519752</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/156800911794519752</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fonseca J, Moradi F, Maddalena LA, Ferreira-Tollstadius B, Selim S, Stuart JA (2019) Resveratrol integrates metabolic and growth effects in PC3 prostate cancer cells-involvement of prolyl hydroxylase and hypoxia inducible factor-1. Oncol Lett 17:697–705. https://doi.org/10.3892/ol.2018.9526</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ol.2018.9526</ArticleId>
            <ArticleId IdType="pubmed">30655819</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haynes J, McKee TD, Haller A, Wang YD, Leung C, Gendoo DMA, Lima-Fernandes E, Kreso A, Wolman R, Szentgyorgyi E, Vines DC, Haibe-Kains B, Wouters BG, Metser U, Jaffray DA, Smith M, O’Brien CA (2018) Administration of hypoxia-activated prodrug evofosfamide after conventional adjuvant therapy enhances therapeutic outcome and targets cancer-initiating cells in preclinical models of colorectal cancer. Clin Cancer Res 24:2116–2127. https://doi.org/10.1158/1078-0432.CCR-17-1715</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-17-1715</ArticleId>
            <ArticleId IdType="pubmed">29476017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang Y, Tian Y, Zhao YY, Xue C, Zhan JH, Liu L, He XB, Zhang L (2018) Efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in nasopharyngeal carcinoma in vitro and in vivo. Cancer Commun (Lond) 38:15. https://doi.org/10.1186/s40880-018-0285-0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40880-018-0285-0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li XR, Lu J, Kan QC, Li XL, Fan Q, Li YQ, Huang RX, Slipicevic A, Dong HP, Eide L, Wang JB, Zhang HQ, Berge V, Goscinski MA, Kvalheim G, Nesland JM, Suo ZH (2017) Metabolic reprogramming is associated with flavopiridol resistance in prostate cancer DU145 cells. Sci Rep 7:5081. https://doi.org/10.1038/s41598-017-05086-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-017-05086-6</ArticleId>
            <ArticleId IdType="pubmed">28698547</ArticleId>
            <ArticleId IdType="pmc">5506068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Minet E, Mottet D, Michel G, Roland I, Raes M, Remacle J, Michiels C (1999) Hypoxia-induced activation of HIF-1, role of HIF-1 alpha-Hsp90 interaction. Febs Lett 460:251–256. https://doi.org/10.1016/s0014-5793(99)01359-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0014-5793(99)01359-9</ArticleId>
            <ArticleId IdType="pubmed">10544245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Newcomb EW, Ali MA, Schnee T, Lan L, Lukyanov Y, Fowkes M, Miller DC, Zagzag D (2005) Flavopiridol downregulates hypoxia-mediated hypoxia-inducible factor-1 alpha expression in human glioma cells by a proteasome-independent pathway: implications for in vivo therapy. Neuro Oncol 7:225–235. https://doi.org/10.1215/S1152851704000997</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1215/S1152851704000997</ArticleId>
            <ArticleId IdType="pubmed">16053697</ArticleId>
            <ArticleId IdType="pmc">1871916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park SY, Jeong KJ, Lee J, Yoon DS, Choi WS, Kim YK, Han JW, Kim YM, Kim BK, Lee HY (2007) Hypoxia enhances LPA-induced HIF-1 alpha and VEGF expression: their inhibition by resveratrol. Cancer Lett 258:63–69. https://doi.org/10.1016/j.canlet.2007.08.011</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.canlet.2007.08.011</ArticleId>
            <ArticleId IdType="pubmed">17919812</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scheibel T, Buchner J (1998) The Hsp90 complex - a super-chaperone machine as a novel drug target. Biochem Pharmacol 56:675–682. https://doi.org/10.1016/s0006-2952(98)00120-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0006-2952(98)00120-8</ArticleId>
            <ArticleId IdType="pubmed">9751071</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sedlacek HH (2001) Mechanisms of action of flavopiridol. Crit Rev Oncol Hemat 38:139–170. https://doi.org/10.1016/s1040-8428(00)00124-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s1040-8428(00)00124-4</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shin DH, Chun YS, Lee DS, Huang LE, Park JW (2008) Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1. Blood 111:3131–3136. https://doi.org/10.1182/blood-2007-11-120576</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2007-11-120576</ArticleId>
            <ArticleId IdType="pubmed">18174379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Volmer AA, Szpilman AM, Carreira EM (2010) Synthesis and biological evaluation of amphotericin B derivatives. Nat Prod Rep 27:1329–1349. https://doi.org/10.1039/b820743g</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/b820743g</ArticleId>
            <ArticleId IdType="pubmed">20556271</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yeo EJ, Ryu JH, Cho YS, Chun YS, Huang LE, Kim MS, Park JW (2006) Amphotericin B blunts erythropoietin response to hypoxia by reinforcing FIH-mediated repression of HIF-1. Blood 107:916–923. https://doi.org/10.1182/blood-2005-06-2564</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2005-06-2564</ArticleId>
            <ArticleId IdType="pubmed">16189267</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang QZ, Tang XD, Lu QY, Zhang ZF, Brown J, Le AD (2005) Resveratrol inhibits hypoxia-induced accumulation of hypoxia-inducible factor-1 alpha and VEGF expression in human tongue squamous cell carcinoma and hepatoma cells. Mol Cancer Ther 4:1465–1474. https://doi.org/10.1158/1535-7163.MCT-05-0198</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-05-0198</ArticleId>
            <ArticleId IdType="pubmed">16227395</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
